Arrowhead Pharmaceuticals, Inc. (ARWR)
NASDAQ: ARWR · Real-Time Price · USD
63.84
-2.41 (-3.64%)
At close: Jan 16, 2026, 4:00 PM EST
64.02
+0.18 (0.28%)
After-hours: Jan 16, 2026, 7:58 PM EST
Arrowhead Pharmaceuticals Stock Forecast
Stock Price Forecast
The 10 analysts that cover Arrowhead Pharmaceuticals stock have a consensus rating of "Strong Buy" and an average price target of $73.7, which forecasts a 15.44% increase in the stock price over the next year. The lowest target is $17 and the highest is $110.
Price Target: $73.7 (+15.44%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Arrowhead Pharmaceuticals stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Aug '25 | Sep '25 | Oct '25 | Nov '25 | Dec '25 | Jan '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 4 | 4 | 4 | 5 | 5 |
| Buy | 3 | 3 | 2 | 2 | 2 | 2 |
| Hold | 2 | 2 | 2 | 4 | 3 | 3 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 8 | 9 | 8 | 10 | 10 | 10 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Piper Sandler | Piper Sandler | Buy Reiterates $100 → $110 | Buy | Reiterates | $100 → $110 | +72.31% | Jan 13, 2026 |
| Goldman Sachs | Goldman Sachs | Hold Maintains $50 → $85 | Hold | Maintains | $50 → $85 | +33.15% | Jan 7, 2026 |
| Morgan Stanley | Morgan Stanley | Hold Maintains $48 → $81 | Hold | Maintains | $48 → $81 | +26.88% | Jan 7, 2026 |
| Chardan Capital | Chardan Capital | Strong Buy Maintains $60 → $80 | Strong Buy | Maintains | $60 → $80 | +25.31% | Jan 7, 2026 |
| Piper Sandler | Piper Sandler | Buy Maintains $70 → $100 | Buy | Maintains | $70 → $100 | +56.64% | Dec 17, 2025 |
Financial Forecast
Revenue This Year
409.50M
from 829.45M
Decreased by -50.63%
Revenue Next Year
277.18M
from 409.50M
Decreased by -32.31%
EPS This Year
-3.29
from -0.01
EPS Next Year
-4.48
from -3.29
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 629.5M | 421.0M | |||
| Avg | 409.5M | 277.2M | |||
| Low | 98.0M | 135.9M |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | -24.1% | 2.8% | |||
| Avg | -50.6% | -32.3% | |||
| Low | -88.2% | -66.8% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | -1.77 | -2.73 | |||
| Avg | -3.29 | -4.48 | |||
| Low | -5.81 | -6.08 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | - | - | |||
| Avg | - | - | |||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.